Passionate
about animal health

CANINE LEISHMANIOSIS:
THE CANILEISH® * VACCINE OBTAINS A EUROPEAN REGISTRATION

Carros - France, 17 March 2011

Following submission of the registration dossier with the European Medicines Agency (EMA) in early 2010, the CVMP, Committee for Medicinal Products for Veterinary Use of the EMA, issued a favourable opinion on 13 January 2011 for CaniLeish®, the first vaccine against canine leishmaniosis in Europe. On 14 March, **the European Commission confirmed this opinion by awarding Virbac a European registration for this vaccine.**

CaniLeish® will initially be launched in Portugal at the end of the first half of 2011.
This will be followed rapidly by launches in other countries in the endemic area: Spain, France, Greece and Italy (not in chronological order). This roll-out takes account of the geographical prevalence of the disease and the time required to build vaccine production up to full capacity.
The launch in Northern European countries from where there is a flow of summer visitors to the endemic area will be part of a second phase.

** The CaniLeish® vaccine has been developed by BVT (Bio Véto Test), a 100% subsidiary of VIRBAC, in partnership with IRD (Institut de Recherche pour le Développement), and VIRBAC's R&D teams. This project is based on an invention patented by the IRD relating to leishmania culture, on which IRD has granted an exclusive patent licence to BVT for the veterinary market.*